The Pharmacogenomics Journal (2020) 20:159–168
https://doi.org/10.1038/s41397-019-0098-9

REVIEW ARTICLE

Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review

Frank Eektimmerman[1,2] · Jesse J. Swen[1,2] · Moenira B. Madhar[1] · Cornelia F. Allaart[3] · Henk-Jan Guchelaar[1,2]

Received: 16 May 2018 / Revised: 15 September 2019 / Accepted: 1 October 2019 / Published online: 17 October 2019

Abstract

Multiple pharmacogenetic studies investigated the effectiveness of methotrexate. However, due to the use of nonvalidated outcomes, lack of validation or conflicting results it remains unclear if genetic markers can help to predict response to MTX treatment. Therefore, a systematic review was performed. PubMed was searched for articles reporting potential pharmacogenetic biomarkers associated ($p < 0.05$) with MTX efficacy using the validated endpoints DAS(28), EULAR, or ACR response criteria. The PICO method was used for study selection, and PRISMA guidelines to prepare the report. Thirty-five studies met the inclusion criteria, providing 39 potential genetic biomarkers in 19 genes. After Bonferroni correction, six genetic biomarkers were associated with the efficacy of MTX: *ATIC* rs7563206; *SLC19A1* rs1051266; *DHFR* rs836788; *TYMS* rs2244500, rs2847153, and rs3786362 in at least one study. Only *SLC19A1* rs1051266 was replicated in an independent cohort and promising for predicting methotrexate efficacy.

Introduction

Low-dose methotrexate (MTX) is considered the "anchor drug" for the treatment of rheumatoid arthritis (RA). The precise mechanism of action of MTX remains to be elucidated, but it is known that MTX is transported over the membrane by multiple solute carriers (SLC) and that intracellular MTX has to be bound to polyglutames molecules by folylpolyglutamate synthase (FPGS) to exert its function. As illustrated in Fig. 1, the polyglutamated MTX affects multiple cellular pathways, e.g., adenosine, de novo purine synthesis, folate, methionine, and de novo pyrimidine synthesis.

In particular, an essential function of the folate pathway is to provide cofactors for key enzymes, such as dihydrofolate reductase (DHFR) that converts dihydrofolate into the folic acid derivative tetrahydrofolate (THF). THF and other derivatives are required for the purine and pyrimidine synthesis, which are important for cell proliferation and cell growth [1]. The methionine pathway is responsible for the synthesis of adenosine, which is an anti-inflammatory agent, alterated by methionine synthase and methionine synthase reductase (MTRR). Further, methionine is a precursor for S-adenosyl-methionine, which is a methyl donor that serves a variety of cellular functions, including DNA methylation [2]. The ubiquitin pathway is not directly related to the other pathways, but has an essential function in homeostasis and recognition of MHC class 1 for the cytotoxic T cells [3].

Approximately one-third of RA patients experience insufficient clinical response to MTX. Pharmacogenetics studies the impact of genetic variation to drug response and genetic variants in the MTX pathways described above may affect the potential effects of methotrexate on inflammation in RA. Indeed, multiple studies reported associations between single nucleotide polymorphisms (SNPs) and the efficacy of MTX. However, to date, none of the proposed markers are applied in clinical practice due to lack of validation or conflicting results. In addition, previous systematic reviews [4–10] described the effect of

Supplementary information The online version of this article (https://doi.org/10.1038/s41397-019-0098-9) contains supplementary material, which is available to authorized users.

✉ Henk-Jan Guchelaar
h.j.guchelaar@lumc.nl

[1] Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands

[2] Leiden Network for Personalised Therapeutics, https://www.lumc.nl/org/lnpt/

[3] Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands



Fig. 1 Intracellular MTX mechanism pathway, divided into the methionine, folate, de novo pyrimidine synthesis, de novo purine synthesis, and adenosine pathway. 10-CHO-THF methylenetetrahydrofolate dehydrogenase, 5,10-CH-THF methyltetrahydrofolate cyclohydrolase, 5–10-MTHF formyltetrahydrofolate synthetase, 5-MTHF L-methylfolate, ABC ATP-binding cassette transporters, ADA adenosine deaminase, ADORA2A adenosine A2A receptor, AICAR 5-aminoimidazole-4-carboxamide ribonucleotide, AMP adenosine monophosphate, AMPD1 adenosine monophosphate deaminase 1 ATIC 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase, ATP adenosine triphosphate, cAMP cyclic adenosine monophosphate, CD37 transmembrane protein, CD39 transmembrane protein, DHF dihydrofolate, DHFR dihydrofolate reductase, DTMP deoxythymidine monophosphate, DTTP deoxythymidine triphosphate, DUMP deoxyuridine monophosphate FAICAR 5-formylaminoimidazole-4-carboxamide ribonucleotide, FPGS folylpoly-γ-glutaminase synthetase, GGH γ-glutamyl hydrolase, IL-10 interleukin-10, IMP inosine monophosphate, IPTA inosine triphosphatase, MS methionine synthase, MTHFD1 methylenetetrahydrofolate dehydrogenase 1, MTHFR methylenetetrahydrofolate reductase, MTRR methionine synthase reductase, MTX methotrexate, MTXPG methotrexate polyglutamate, NT nucleoside transporter, SHMT-1 serine hydroxymethyltransferase 1, SLC solute carrier, THF tetrahydrofolate, TYMS thymidylate synthase

SNPs on the efficacy of MTX, but some included studies with MTX in different diseases such as juvenile idiopathic arthritis [10] or leukemia [5] or applied nonvalidated endpoints, such as red blood cell MTX polyglutamate concentrations [5, 11] or physicians' assessment of patient's response [9].

The goal of this review is to systematically explore which SNPs related to MTX pharmacology are associated with efficacy in RA by selecting only studies with the validated endpoints DAS(28), European League Against Rheumatism (EULAR), or American College of Rheumatology (ACR) response criteria [12, 13].

Methods

Data extraction and identification of eligible studies

Identification and selection of studies were performed according to the PICO method [14]. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to prepare the report [15]. PubMed was used to identify and extract all relevant articles published between April 2002 and March 2017. Search terms consisted of *rheumatoid arthritis*, *methotrexate*, *pharmacogenetics,* and SNP. The full search string is provided in Supplementary File S1. Also, we manually checked reference lists from reviews to identify relevant cross-references.

Records were screened on title and abstract. Comments, editorials, narrative reviews, letters (without original data), abstracts, and publications in languages other than English were excluded. Only studies utilizing the DAS(28), the response criteria of the ACR or the EULAR were eligible for inclusion. Included SNPs were analyzed under the additive, allelic, genotypic or haploid genetic model, and had at least one association with either DAS(28), ACR or EULAR response ($p < 0.05$, uncorrected for multiple testing).

SNPs were divided into MTX-related pathways: adenosine, de novo purine synthesis, transporters, polyglutamation, folate, methionine, de novo pyrimidine synthesis, and ubiquitin. Results from included studies were summarized, and reported odds ratio (OR) with 95% confidence interval (CI), *p*-value, type of association and SNP ID were collected. Finally, SNPs were checked on linkage disequilibrium by SNP Annotation and Proxy Search (SNAP, Broad Institute) [16], with the LD threshold of $R^2 > 0.8$.

To control the risk of false positive findings, Bonferroni correction was applied when no correction for multiple testing was performed in the original study by calculating a significant cut-off *p*-value at α/n ($p = 0.05$ divided by the number of tested SNPs within each study). SNPs were



Fig. 2 Study flow diagram of the systematic review inclusion [15]. MTX methotrexate, MAF minimum allele frequency, ACR American College of Rheumatology, DAS Disease Activity Score, EULAR European League Against Rheumatism

significantly associated if the *p*-value was <0.05 after Bonferroni correction. Ultimately meta-analyses were used to support our findings of potential significant SNPs.

Results

Study selection

Figure 2 shows the results of the study selection. Initially, 115 publications were identified. We excluded 30 comments, editorials, letters, narrative reviews, and seven non-English written publications. Of the remaining 78 studies, 41 were excluded because none of our defined endpoints was reported and one because the report of the study could not be obtained. By cross-references, three more studies were included. In total, 35 original studies were available for analysis in this systematic review and seven meta-analyses were used to support our findings.

Study characteristics

Most studies (34 out of 35) were candidate gene studies investigating 1–35 polymorphisms. There was one genome-wide association study (GWAS) investigating 559,007 polymorphisms [17]. The mean study population of the studies was 197 patients (ranging from 48 to 422 patients). Most studies used the EULAR good response criteria (32%), tested <10 SNPs (76%), were conducted in Europe with RA patients of (self-)reported Caucasian origin. The average rate of good EULAR response to MTX monotherapy at $t = 6$ months was 55%, ranging from 23 [18] to 85% [19].

The included studies reported 39 SNPs in 20 genes associated with either DAS(28), EULAR, or ACR response with a p-value < 0.05. After Bonferroni correction, 16 SNPs in 10 genes remained significantly associated with MTX efficacy.

Adenosine pathway—ADA, ADORA2A, AMPD1, and ITPA

AMPD1 rs17602729 (allelic T) showed a significant association with DAS28 ≤ 3.2 (OR: 6.73, 95% CI: 1.74–26.01) between $t = 3$ and 6 months [20]. However, this was not confirmed with the genotypic CC model at $t = 6$ months [21]. None of the other SNPs in the adenosine pathways—*ADA* (rs244076), *ADORA2A* (rs5751876), and *ITPA* (rs1127354)—were significantly associated with the MTX response at $t = 6$ months using allelic or genotypic genetic models.

De novo purine synthesis—ATIC

Four SNPs in *ATIC* (rs2372536 [22], rs4673993 [23], rs7563206 [1], and rs12995526 [1]) had at least one study reporting a significant association with MTX efficacy. *ATIC* rs7563206 (allelic T carrier) was tested in one study, and showed an association with MTX nonresponse with the endpoint DAS28 ≤ 3.2 at $t = 6$ months (OR: 0.20 95% CI:0.09–0.46) [1]. At $t = 6$ months, *ATIC* rs4673993 (genotypic TT) showed a significant association with a better response (DAS28 ≤ 3.2, OR:3.86 95% CI:1.50–9.91), while rs12995526 (allelic T carriers) showed a significant association with a worse response (DAS28 ≤ 3.2, OR:0.23 95% CI:0.10–0.53) to MTX [23].

ATIC (rs2372536, genotype CC) was significantly associated with DAS ≤ 2.4 at $t = 6$ months, with an OR of 2.5 (95% CI: 1.3–4.8) [22]. Three other studies—using *ATIC* rs2372536 genotypic CC at $t = 6$ months—reported no significant association, of which one study reported that the CC genotype was related to MTX nonresponse with a OR below 1.0 (OR:0.27, 95% CI: 0.08–0.92) [1, 20, 24].

Transporters—ABCB1C1, ABCC1, SLC19A1 (RFC1), and SLC22A11

None of the SNPs in *ABCB1* (rs1045642), *ABCC1* (rs246240 and rs3784864), and *SLC22A11* (rs11231809)

were significantly associated with DAS28 ≤ 3.2 or EULAR good response at $t = 6$ months. The most studied genetic *SLC19A1* SNP was rs1051266, which was investigated in 11 studies. Three studies reported a significant association with MTX efficacy at $t = 6$ months using ACR20 or DAS28 and different genetic models (either allelic A carriers, genotypic GG or genotypic AA). Other studies did not investigate the same genetic models, using the same efficacy endpoints with the same time evaluation point for *SLC19A1* rs1051266.

Polyglutamation—FPGS and GGH

FPGS rs4451422 (allelic C carriers) was associated with MTX efficacy using EULAR good response at $t =$ 6 months, with an OR of 0.73 (0.54–0.98) [17]. *FPGS* SNPs (rs1544105, rs10106, and rs10987742) and GGH SNPS (rs2305558 and rs1800909) were not significantly associated with MTX efficacy.

Folate pathway—DHFR, MTHFR, and SHMT

Both *MTHFR* rs1801131 (A1298C) and rs1801133 (C677T) have frequently been studied (>10 studies). One study showed a significant association with *MTHFR* rs1801133 CC genotype with DAS28 ≤ 3.2 at $t = 6$ months, with an OR of 3.4 [25]. Three other studies investigated the association of *MTHFR* genotypic CC at $t = 6$ months, and did not find an association using other endpoints (EULAR GR, ΔDAS44 < 0.6, and ACR20) [26–28]. For two other SNPs in *MTHFR* (rs17421511 and rs1476413) there was no significant association with MTX response. Also, no association was found between *MTHFD1* rs17850560 or *SHMT-1* rs1979277 with MTX response using DAS28(≤3.2) or EULAR GR. *DHFR* rs836788 was associated in one study with EULAR response at $t = 6$ months, with an OR of 1.44 (95% CI: 1.09–1.93) and 1.47 (95% CI: 1.09–1.96), respectively for the allelic A carriers and the genotypic AA [17].

Methionine pathway—MTR and MTRR

Six studies investigated the role of the *MTR A2756G* (rs1805087), of which one study reported a significant association [19]. Here, *MTR* rs1805087 was associated with MTX efficacy at $t = 12$ month, and the use of the endpoint EULAR good response with the genotypic AA (OR was not available). Other studies could not confirm the association with rs1805087, using the DAS28 with genotypic AA on $t = 4$ months [29], EULAR GR with the allelic G carriers on $t = 4$ months [30], or with the DAS28 ≤ 3.2 allelic G carriers on $t = 6$ months [31]. No significant association was reported with *MTRR* rs162040 and rs1801394.

De novo pyrimidine pathway—TYMS

TYMS rs2244500, rs2847153, and rs3786362 were all significantly associated with EULAR good response at $t =$ 6 months and had OR of resp. 1.48. 1.92, 0.51, and 2.76 [17, 21]. No other studies investigated the effect of *TYMS* with MTX response.

Ubiquitin pathway—CUL1

Negi et al. investigated the association of *CUL1* haplotypes with MTX efficacy using the DAS28 ≤ 3.2 at $t = 6$ months [32]. Here, *CUL1* rs122571 haplotype A-T-T (OR: 2.83, 95% CI: 1.33–6.04) and rs243480 haplotype G-T-T (OR: 0.16, 95% CI 0.04–0.67) were significant.

KIR gene

One study tested multiple length variants of the KIR gene and showed that the full-length *KIR2DS4* gene was significantly associated with DAS28 ≤2.5 (OR: 0.4344, 95% CI: 0.215, 0.987) at $t = 6$ months [33]. Here, possessing the *KIRSDS4* gene had a lower chance of responding to MTX treatment.

Most promising genetic variants related to MTX efficacy

Table 1 lists the most promising SNPs that were significantly associated with MTX efficacy after Bonferroni correction without having conflicting results from other studies. For instance, it is *ATIC* rs467393 genotypic TT with better response, while allelic T carriers results in worse response or lacks validation.

The most promising SNPs were derived from the pathways de novo purine (*ATIC*), de novo pyrimidine (*TYMS*), and transporters (*SLC19A1*). The SNPs have a minor allele frequency > 0.2, except TYMS rs3786362 (MAF < 0.2 for all races). *ATIC* rs7563206 and TYMS rs2244500 were found significantly associated with an OR below 1.0, while the other eight SNPs had an OR between 1.42 and 2.83. The used genetic models were with either allelic, genotypic or haplotype. No linkage disequilibrium ($R^2 > 0.8$) was observed for any of the SNPs in Table 2. *SLC19A1* rs1051266 was tested in multiple studies and positively associated in three studies.

Of the six promising SNPs, *ATIC* rs7563206, *TYMS* rs2847153, and rs3786362 were associated with non-response to MTX, while *SLC19A1* rs1051266, *DHFR* rs836788, and *TYMS* rs2244500 were associated with response to MTX. ORs range from 0.2 to 0.68 for MTX nonresponse and 1.42–2.76 for MTX response. The six SNPs had a MAF of >0.2 in all races except for *TYMS*

Table 1 Most promising SNPs that were significantly associated with MTX efficacy

Gene	SNP	Location	MAF					Association	OR [95% CI]	Study
			AF	AFR	AMR	EUR	SAS			
SLC19A1	rs1051266[a]	21:45537880	0.4886	0.3268	0.5821	0.5487	0.5941	Genotypic AA	1.78 [1.13–2.81]	Drozdzik et al. [41]
ATIC	rs7563206	2:215325931	0.4018	0.5129	0.4280	0.4871	0.3292	Allelic T carriers	0.20 [0.09–0.46]	Lima et al. [1]
DHFR	rs836788	5:80616225	0.4235	0.5106	0.3631	0.3807	0.4335	Allelic A carriers	1.44 (1.08–1.93)	Senapati et al. [17]
								Genotypic AA	1.47 (1.09–1.96)	Senapati et al. [17]
TYMS	rs2244500	18:661005	0.6160	0.8101	0.4251	0.4612	0.5706	Allelic A carriers	1.48 [1.12–1.94]	Senapati et al. [17]
								Genotypic AA	1.48 [1.13–1.94]	Senapati et al. [17]
TYMS	rs2847153	18:661647	0.2901	0.2428	0.2305	0.2097	0.3865	Allelic A carriers	0.68 [0.51–0.91]	Senapati et al. [17]
TYMS	rs3786362	18:662247	0.0623	0.0015	0.0490	0.0000	0.1063	Allelic G carriers	0.51 [0.30–0.86]	Senapati et al. [17]

[a]Confirmed by the meta-analyses of Kung et al. [49] and Li et al. [50]

AFR African population, *AMR* American population, *EAS* East Asian population, *EUR* European population, *SAS* South Asian population, derived from the HapMap project

rs3786362 which is sparse and even does not occurred in the European population.

Despite the findings of one significant association of *ATIC* rs473993 and rs12995526, *AMPD1* rs17602729, *MTHFR* rs1801133, and *MTR* rs180508, and FPGS rs4451422, we did not mark those as promising genetic variants due to conflicting results. Also, we did not include the full-length KIR2DS4 gene as a promising genetic marker for the response to MTX, due to the complexity of the determination of the whole KIR2DS4 gene (with 15,894 bases) and the fact that it is not one SNP. This was also the case of *CUL1* that was significantly associated with MTX response for two haplotypes; A-T-T (rs122571) and G-T-T (rs243480).

Discussion

This systematic review assesses the effect of genetic variation on the efficacy of MTX in RA using the validated endpoints DAS, EULAR, or ACR response criteria. After Bonferroni correction for multiple testing, we identified six genetic biomarkers related to MTX efficacy. Of these, *SLC19A1* rs1051266 had the most convincing evidence with two independent studies showing significant associations. Other potentially promising SNPs are *ATIC* rs7563206, *DHFR* rs836788, *TYMS* rs2244500, rs2847153, and rs3786362, but these lack replication studies. The six genetic biomarkers could have clinical implications for the disease outcome of RA. In fact, *SLC19A* rs1051266, *DHFR* rs836788, and *TYMS* rs2244500 showed a 40% or more increased chance of the effectiveness of MTX, and *ATIC* rs7563206 and rs378636, and *TYMS* rs2847153 showed 45% or more chance of the reduced effectiveness of MTX. Still we believe that additional studies are necessary before implementing pharmacogenetic testing for these SNPs in the treatment of RA.

A limitation of the investigated studies in this systematic review is the difference in the evaluation time points for measuring MTX efficacy. MTX is a slow-acting prodrug that becomes active when polyglutamated in the cells. The process of polyglutamation is slow and takes up to 27.5 weeks (range 6.6–62.0 weeks) to reach steady state [34]. This delay in steady-state polyglutamation explains the relatively long time to clinical response, and therefore most studies had the endpoint set to 6 months after the start of MTX therapy. However, some studies evaluated response earlier than $t = 6$ months, while MTX may not yet have exerted its full potential. Furthermore, the genotypic or allelic genetic models were often used, when in fact the hypothesis-free driven additive genetic model seems more appropriate because the underlying genetic model is unknown.

Another limitation is that most studies tested with univariate analysis, without taking into account baseline variables (multivariate testing), such as gender, smoking status, disease severity which are known to influence response to MTX. Most drug-gene interaction studies were explorative, with the use of retrospective data and lack validation. Pharmacogenetic testing in RA remains limited mainly because the evidence for drug-gene interactions are marginal. MTX is involved in multiple pathways with different genes. Yet, most pharmacogenetic studies were candidate studies that tested only a single or a small number of SNPs, but not a combination of multiple genes or pathways [35]. To get clear evidence, additional studies with the use of a combination of multiple genes are needed. This review can show a basis, to test all suggestive SNPs together in association with the efficacy of MTX.

The strength of our study is that a systematic approach was used to identify SNPs and the selection of the articles

Table 2 Genetic biomarkers related to MTX efficacy

Gene	SNPs	Genetic model	Endpoint	Time of response evaluation (months)	*N*	Reported *P*-value	OR (95% CI)	Study
Adenosine pathway								
ADA	rs244076	Allelic A carriers	EULAR GR	6	281	**0.02**	1.66 (1.01–2.75)	Sharma et al. [21]
		Genotypic AA	EULAR GR	6	281	0.17	–	Sharma et al. [21]
ADORA2A	rs5751876	Allelic C carriers	EULAR GR	6	281	**0.04**	1.55 (1.01–2.37)	Sharma et al. [21]
		Genotypic TT	EULAR GR	6	281	0.12	–	Sharma et al. [21]
AMPD1	rs17602729	Allelic T carriers	DAS ≤ 2.4	6	204	**<0.05**	2.1 (1.0–4.5)	Wessels et al. [22]
	(C34T)	Allelic T carriers	DAS28 ≤ 3.2	3–6	205	**0.006***	6.73 (1.74–26.01)	Grabar et al. [20]
		Allelic C carriers	EULAR GR	6	281	0.39	–	Sharma et al. [21]
		Genotypic CC	EULAR GR	6	281	0.38	–	Sharma et al. [21]
ITPA	rs1127354	Genotypic CC	DAS ≤ 2.4	6	204	**<0.05**	2.7 (1.1–8.1)	Wessels et al. [22]
	(C94A)	Allelic A carriers	EULAR GR	4	255	**0.006**	2.95 (1.36–6.38)	Dervieux et al. [30]
De novo purine synthesis pathway								
ATIC	rs2372536 (C347G)	Allelic C carriers	DAS28 ≤ 3.2	6	233	0.568	0.83 (0.43–1.69)	Lima et al. [1]
		Allelic C carriers	EULAR GR	6	281	0.96	–	Sharma et al. [21]
		Allelic C carriers	EULAR GR	12	98	0.56	–	James et al. [19]
		Allelic C carriers	EULAR GR	6	319	0.94	0.98 (0.67–1.43)	Muralidharan et al. [36]
		Allelic C carriers	ACR 20 & 50	12	217	NS	–	Ghodke-Puranik et al. [18]
		Allelic C carriers	DAS28 ≤ 2.4	6	422	0.229	1.29 (0.87–1.91)	Kurzawski et al. [24]
		Allelic G carriers	EULAR GR	4	255	0.71	1.09 (0.66–1.80)	Dervieux et al. [30]
		Genotypic GG	DAS28	6	170	NS	–	Hayashi et al. [37]
		Genotypic GG	DAS28 ≤ 2.4	6	422	**0.005**	2.40 (1.30–4.42)	Kurzawski et al. [24]
		Genotypic CC	EULAR GR	6	281	0.17	–	Sharma et al. [21]
		Genotypic CC	EULAR GR	12	98	0.85	–	James et al. [19]
		Genotypic CC	DAS28 ≤ 3.2	6	233	**0.036**	0.27 (0.08–0.92)	Lima et al. [1]
		Genotypic CC	DAS28 ≤ 3.2	3–6	208	NS	–	Grabar et al. [20]
		Genotypic CC	DAS ≤ 2.4	6	205	**0.007***	2.5 (1.3–4.8)	Wessels et al. [22]
		Genotypic CC	EULAR GR	6	61	0.12	1.95 (0.83–4.56)	Salazar et al. [38]
	rs4673993	Allelic C carriers	DAS28 ≤ 3.2	6	233	**0.036**	0.27 (0.08–0.92)	Lima et al. [1]
		Genotypic TT	DAS28 ≤ 3.2	6	120	**0.006***	3.86 (1.50–9.91)	Lee et al. [23]
		Genotypic TT	DAS28 ≤ 3.2	6	233	0.950	0.98 (0.51–1.89)	Lima et al. [1]
	rs7563206	Allelic T carriers	DAS28 ≤ 3.2	6	233	**<0.001***	0.20 (0.09–0.46)	Lima et al. [1]
		Genotypic TT	DAS28 ≤ 3.2	6	233	0.558	0.81 (0.40–1.65)	Lima et al. [1]
	rs12995526	Allelic T carriers	EULAR GR	6	233	**0.001***	0.23 (0.10–0.53)	Lima et al. (2016) [1]
		Allelic T carriers	DAS28 ≤ 2.4	6	422	0.112	0.71 (0.47–1.07)	Kurzawski et al. [24]
		Genotypic TT	DAS28 ≤ 2.4	6	422	0.138	0.65 (0.38–1.10)	Kurzawski et al. [24]
		Genotypic TT	EULAR GR	6	233	0.413	0.74 (0.37–1.51)	Lima et al. [1]
		Genotypic CC	EULAR GR	6	61	0.22	1.78 (0.70–4.52)	Salazar et al. [38]
Transporters								
ABCB1	rs1045642	Genotypic CT	DAS28 ≤ 3.2	6	281	**0.01**	1.97 (1.13–3.42)	Sharma et al. [39]
	(C3435T)	Genotypic CC	DAS28 ≤ 3.2	6	281	**0.01**	0.32 (0.13–0.80)	Sharma et al. [39]
		Genotypic CC	DAS < 2.4	6	186	0.769	–	Kooloos et al. [40]
		Allelic C carriers	DAS < 2.4	6	186	0.082	–	Kooloos et al. [40]
ABCC1	rs246240	Allelic G carriers	DAS28 ≤ 3.2	6	233	**0.008**	5.47 (1.56–19.25)	Lima et al. [31]
		Genotypic GG	DAS28 ≤ 3.2	6	233	0.846	0.76 (0.05–11.46)	Lima et al. [31]
	rs3784864	Allelic A carriers	EULAR GR	6	233	0.402	0.64 (0.23–1.80)	Lima et al. [31]
		Genotypic AA	EULAR GR	6	233	**0.015**	4.24 (1.32–13.65)	Lima et al. [31]
SLC19A1/RFC1	rs1051266 (G80A)	Allelic A carriers	ACR 20 & 50	12	217	**0.030**	2.20 (1.1–4.4)	Ghodke-Puranik et al. [18]
		Allelic A carriers	EULAR GR	12	98	**0.009**	–	James et al. [19]
		Allelic A carriers	ACR 20	6	174	**0.021***	3.32 (1.26–8.79)	Drozdzik et al. [41]
		Allelic A carriers	DAS28 ≤ 3.2	6	233	0.672	1.23 (0.47–3.18)	Lima et al. [31]
		Allelic A carriers	DAS28 ≤ 3.2	6	281	NS	–	Sharma et al. [39]
		Allelic A carriers	EULAR GR	6	225	0.28	1.24 (0.85–1.81)	Muralidharan et al. [42]
		Allelic A carriers	EULAR GR	4	255	0.07	1.63 (0.95–2.79)	Dervieux et al. [30]
		Genotypic AA	EULAR GR	12	98	**0.036**	–	James et al. [19]
		Genotypic AA	ACR 20%	6	174	**0.013***	1.78 (1.13–2.81)	Drozdzik et al. [41]
		Genotypic AA	DAS28 ≤ 3.2	6	233	0.924	1.05 (0.36–3.09)	Lima et al. [31]
		Genotypic AA	DAS28 ≤ 3.2	6	281	NS	–	Sharma et al. [39]
		Genotypic GG	DAS28	4	255	0.27	–	Dervieux et al. [30]
		Genotypic GG	DAS28	6	170	**0.0018***	2.27 (1.36–3.80)	Hayashi et al. [37]
		Genotypic GG	EULAR GR	6	76	0.602	–	Moya et al. [43]
		Genotypic GG	EULAR GR	6	54	NS	–	Chatzikyriakidou et al. [44]
		Genotypic GG	DAS28 ≤ 3.2	6	240	NS	–	Świerkot et al. [25]
		Genotypic GG	EULAR GR	6	225	0.56	0.81 (0.46–1.43)	Muralidharan et al. [42]
SLC22A11	rs11231809	Genotypic AA	DAS28 ≤ 3.2	6	233	**0.031**	0.19 (0.04–0.86)	Lima et al. [31]
		Allelic A carriers	DAS28 ≤ 3.2	6	233	0.116	0.44 (0.16–1.22)	Lima et al. [31]

Table 2 (continued)

Gene	SNPs	Genetic model	Endpoint	Time of response evaluation (months)	*N*	Reported *P*-value	OR (95% CI)	Study
Polyglutamation								
FPGS	rs4451422	Allelic A carriers	DAS28 ≤ 3.2	6	232	0.077	0.52 (0.025–1.07)	Lima et al. [1]
		Allelic C carriers	EULAR GR	6	457	**0.035***#	0.73 (0.54–0.98)	Senapati et al. [17]
		Genotypic AA	DAS28 ≤ 3.2	6	232	0.27	1.57 (0.70–3.49)	Lima et al. [1]
		Genotypic CC	EULAR GR	6	457	**0.05**#	0.72 (0.52–1.00)	Senapati et al. [17]
	rs1544105	Allelic A carriers	EULAR GR	6	281	**0.008**	3.47 (1.19–10.12)	Sharma et al. [21]
		Allelic G carriers	DAS28 ≤ 3.2	6	233	0.316	1.53 (0.68–3.60)	Lima et al. [1]
		Allelic G carriers	DAS28 ≤ 3.2	6	281	**0.043**	1.55 (1.01–2.37)	Sharma et al. [39]
		Allelic A carriers	DAS28 ≤ 2.4	6	422	0.919	0.96 (0.65–1.43)	Kurzawski et al. [24]
		Genotypic GG	DAS28 ≤ 3.2	6	233	0.115	0.56 (0.27–1.15)	Lima et al. [1]
		Genotypic AA	DAS28 ≤ 2.4	6	422	0.398	0.77 (0.44–1.36)	Kurzawski et al. [24]
	rs10106(A1994G)	Allelic C carriers	DAS28 ≤ 2.4	6	422	0.841	0.94 (0.64–1.40)	Kurzawski et al. [24]
		Allelic C carriers	DAS < 2.4	6	352	0.9	2.90 (1.50–5.40)	van der Straaten et al. [45]
		Allelic A carriers	DAS28 ≤ 3.2	6	233	0.317	1.50 (0.68–3.29)	Lima et al. [1]
		Allelic A carriers	DAS ≤ 2.4	6	186	0.638	–	Wessels et al. [46]
		Allelic A carriers	DAS ≤ 2.4	6	352	NS	–	van der Straaten et al. [45]
		Genotypic AA	DAS ≤ 2.4	6	186	0.128	–	Wessels et al. [46]
		Genotypic AA	DAS28 ≤ 3.2	6	233	0.070	0.51 (0.25–1.06)	Lima et al. [1]
		Genotypic TT	EULAR GR	6	76	**0.041**	–	Moya et al. [43]
		Genotypic CC	DAS28 < 2.4	6	422	0.253	0.70 (0.69–1.24)	Kurzawski et al. [24]
	rs10987742	Genotypic GG	EULAR GR	6	76	**0.033**	–	Moya et al. [43]
GGH	rs2305558	Allelic A carriers	EULAR GR	6	457	**0.05#**	1.46 (0.98–2.17)	Senapati et al. [17]
		Genotypic AA	EULAR GR	6	457	0.23#	1.51 (0.74–3.08)	Senapati et al. [17]
	rs1800909	Allelic C carriers	DAS ≤ 2.4	3	352	**0.036**	2.1 (1.0–4.7)	van der Straaten et al. [45]
	(C16T)	Allelic C carriers	DAS ≤ 2.4	6	352	NS	–	van der Straaten et al. [45]
		Allelic C carriers	EULAR GR	4	255	0.66	1.11 (0.68–1.83)	Dervieux et al. [30]
		Allelic T carriers	DAS ≤ 2.4	6	186	0.705	–	Wessels et al. [46]
		Genotypic TT	DAS ≤ 2.4	6	186	0.308	–	Wessels et al. [46]
Folate pathway								
DHFR	rs836788	Allelic A carriers	EULAR GR	6	457	**0.014***#	1.44 (1.08–1.93)	Senapati et al. [17]
		Genotypic AA	EULAR GR	6	457	**0.011***#	1.47 (1.09–1.96)	Senapati et al. [17]
	rs12517451	Allelic A carriers	EULAR GR	6	457	**0.05**#	1.35 (0.99–1.85)	Senapati et al. [17]
		Genotypic AA	EULAR GR	6	457	**0.016**#	1.56 (1.07–2.26)	Senapati et al. [17]
	rs408626	Genotypic	ΔDAS	6	125	**0.050**	–	Milic et al. [47]
	(-317)	Genotypic	EULAR GR	6	125	0.2	–	Milic et al. [47]
	rs1643650	Additive	EULAR GR	6	61	**0.026**	0.31 (0.10–0.96)	Salazar et al. [38]
MTHFR	rs17421511	Additive	EULAR GR	6	61	**0.024**	3.35 (1.10–10.24)	Salazar et al. [38]
	rs1801131 (A1298C)	Additive	EULAR GR	6	61	**0.08**	2.19 (0.89–5.37)	Salazar et al. [38]
		Allelic A carriers	ACR 20 & 50	12	217	**0.020**	2.6 (1.1–5.8)	Ghodke-Puranik et al. [18]
		Allelic A carriers	EULAR GR	12	98	1.00	–	James et al. (2008) [19]
		Allelic A carriers	ACR20	6	69	0.56	–	Taraborelli et al. [28]
		Allelic C carriers	DAS28 ≤ 3.2	6	233	**0.045**	0.51 (0.26–0.98)	Lima et al. [31]
		Allelic C carriers	EULAR GR	4	255	0.66	0.89 (0.54–1.46)	Dervieux et al. [30]
		Genotypic AA	ΔDAS44 < 1.2	6	186	**0.014**	2.30 (1.18–4.41)	Wessels et al. [27]
		Genotypic AA	ACR20	6	69	0.35	–	Taraborelli et al. [28]
		Genotypic AA	EULAR GR	12	98	0.92	–	James et al. [19]
		Genotypic AA	DAS28 ≤ 3.2	6	240	NS	–	Świerkot et al. [25]
		Genotypic	DAS28	4	48	NS	–	Dervieux et al. [29]
		Genotypic CC	DAS28 ≤ 3.2	6	120	0.84	0.90 (0.40–2.02)	Lee et al. [23]
		Genotypic CC	DAS28 ≤ 3.2	6	233	0.91	1.07 (0.35–3.28)	Lima et al. [31]
		Genotypic AA	EULAR GR	6	120	0.23	–	Soukup et al. [48]
	rs1476413	Additive	EULAR GR	6	61	**0.0086**	3.56 (1.28–9.91)	Salazar et al. [38]
	rs1801133 (C677T)	Additive	EULAR GR	6	61	0.53	0.73 (0.27–1.98)	Salazar et al. [38]
		Allelic T carriers	ACR 20 & 50	12	217	NS	–	Ghodke-Puranik et al. [18]
		Allelic T carriers	EULAR GR	4	255	0.86	1.04 (0.63–1.72)	Dervieux et al. [30]
		Allelic C carriers	EULAR GR	12	98	0.39	–	James et al. [19]
		Allelic C carriers	ACR20	6	69	0.34	–	Taraborelli et al. [28]
		Allelic C carriers	DAS28 ≤ 3.2	6	233	**0.019**	3.86 (1.25–11.89)	Limaet al. [1]
		Genotypic CC	EULAR GR	6	113	NS	–	Aggarwal et al. [26]
		Genotypic CC	ΔDAS44 < 0.6	6	186	**0.044**	2.73 (1.03–7.26)	Wessels et al. [27]
		Genotypic CC	ACR20	6	69	0.26	–	Taraborelli et al. [28]
		Genotypic CC	EULAR GR	12	98	0.64	–	James et al. [19]
		Genotypic CC	DAS28 ≤ 3.2	6	240	**0.001***	3.4	Świerkot et al. [25]
		Genotypic TT	DAS28	4	48	NS	–	Dervieux et al. [29]

Table 2 (continued)

Gene	SNPs	Genetic model	Endpoint	Time of response evaluation (months)	*N*	Reported *P*-value	OR (95% CI)	Study
		Genotypic TT	EULAR GR	4	48	**<0.05**	22.2 (1.2–42.2)	Dervieux et al. [29]
		Genotypic TT	EULAR GR	6	120	0.432	1.41 (0.51–4.55)	Soukup et al. [48]
MTHFD1	rs17850560 (G1958A)	Genotypic GG	DAS28 ≤ 3.2	3–6	208	**0.021**	4.67 (1.27–17.26)	Grabar et al. [20]
		Genotypic GG	DAS ≤ 2.4	6	186	0.101	–	Wessels et al. [22]
		Allelic A carriers	EULAR GR	4	255	0.11	1.62 (0.90–2.92)	Dervieux et al. [30]
SHMT-1	rs1979277	Genotypic	DAS28	4	48	**<0.05**	7.4 (1.0–56.4)	Dervieux et al. [29]
	(C1420T)	Allelic T carrier	EULAR GR	4	255	0.53	0.85 (0.52–1.40)	Dervieux et al. [30]
Methionine pathway								
MTR (MS)	rs1805087 (A2756G)	Allelic A carriers	EULAR GR	12	98	0.06	–	James et al. [19]
		Allelic A carriers	ACR 20 & 50	12	217	NS	–	Ghodke-Puranik et al. [18]
		Allelic G carriers	EULAR GR	4	255	0.41	1.23 (0.73–2.10)	Dervieux et al. [30]
		Allelic G carriers	DAS28 ≤ 3.2	6	233	**0.017**	0.42 (0.20–0.86)	Lima et al. [31]
		Genotypic AA	EULAR GR	12	98	**0.003***	–	James et al. [19]
		Genotypic AA	DAS28	4	255	NS	–	Dervieux et al. [29]
		Genotypic GG	DAS28 ≤ 3.2	6	233	0.247	0.27 (0.03–2.51)	Lima et al. [31]
MTRR	rs162040	Allelic C carriers	EULAR GR	6	457	**0.04**	1.45 (1.00–2.10)	Senapati et al. [17]
		Genotypic CC	EULAR GR	6	457	**0.02**	2.22 (1.11–4.43)	Senapati et al. [17]
	rs1801394 (A66G)	Allelic A carriers	DAS28 ≤ 3.2	6	233	**0.041**	2.16 (1.03–4.53)	Lima et al. [31]
		Allelic A carriers	ACR 20 & 50	12	217	NS	–	Ghodke-Puranik et al. [18]
		Genotypic AA	DAS28	4	48	NS	–	Dervieux et al. [29]
		Genotypic AA	DAS28 ≤ 3.2	6	233	**0.046**	2.36 (1.01–5.52)	Lima et al. [31]
De novo pyrimidine pathway								
TYMS	rs2244500	Allelic A carriers	EULAR GR	6	457	**0.005*#**	1.48 (1.12–1.94)	Senapati et al. [17]
		Genotypic AA	EULAR GR	6	457	**0.004*#**	1.48 (1.13–1.94)	Senapati et al. [17]
	rs2847153	Genotypic AA	EULAR GR	6	61	0.26	1.92 (0.62–5.97)	Salazar et al. [38]
		Allelic A carriers	EULAR GR	6	457	**0.009*#**	0.68 (0.51–0.91)	Senapati et al. [17]
		Genotypic AA	EULAR GR	6	457	**0.04#**	0.71 (0.52–0.98)	Senapati et al. [17]
	rs3786362	Allelic G carriers	EULAR GR	6	457	**0.011*#**	0.51 (0.30–0.86)	Senapati et al. [17]
		Genotypic GG	EULAR GR	6	457	0.99#	–	Senapati et al. [17]
Ubiquitin pathway								
CUL1	rs122571	Haplotype A-T-T	DAS28 ≤ 3.2	6	29	**0.0051***	2.83 (1.33–6.04)	Negi et al. [32]
	rs243481	Haplotype G-C-T	DAS28 ≤ 3.2	6	74	**0.05**	1.42 (1.0–2.02)	Negi et al. [32]
	rs243480	Haplotype G-T-T	DAS28 ≤ 3.2	6	25	**0.0045***	2.83 (1.33–6.04)	Negi et al. [32]
Other								
KIR	2DS4 gene	Full-length	DAS28 ≤ 2.5	6	312	**0.0334***	0.43 (0.215–0.987)	Majorczyk et al. [33]

P values marked in bold *p*-values have a reported *p*-value below 0.05. *P*-values marked with an asterisk (*) were significantly associated after multiple testing correction (Bonferroni correction, $p < 0.05$). *P*-values marked with hash (#) have a reported *P*-values that was already corrected by multiple testing

BF Bonferroni *EULAR GR* European league against rheumatism good response criteria, *ACR* American College of Rheumatology, *OR* odds ratio, CI confidence interval, *SNPs* single nucleotide polymorphisms, *NS* not significant

was performed according to the PRISMA guidelines. Another strength is that only validated outcome criteria were used and that adjustment for multiple testing by Bonferroni correction was applied for the included studies. A potential weakness of this review is that only English publications were included. This results in the exclusion of seven non-English studies, and important findings could have been missed. Another weakness was the limited sample size of some studies and the lack of power analysis to check the validity of the outcomes.

Finally, a common limitation of systematic reviews is publication bias. Meaning that important—albeit negative—results were never published, which could lead to misinterpretation of the actual findings. Another limitation was that not all studies were performed with MTX monotherapy, and therefore the effect on response could be influenced by other DMARDs. Several meta-analyses have been performed on pharmacogenetics biomarkers for the efficacy or toxicity of MTX in RA. Of our promising SNPs, *SLC19A1* rs1051266 with the genotypic AA (vs AG/AG) was tested in MTX efficacy in three meta-analyses. Two meta-analyses, conducted by Li et al. [50] and Chen et al. (2016), confirmed the significant association with an OR of 1.42 (95% CI: 1.04–1.93) and 1.49 (CI: 1.17–1.90), respectively. However, the third meta-analysis by Chen et al. (2016) showed substantial heterogeneity (I^2) of 72% for the allelic model and thus represented inconsistencies of the pooled studies and affects the validity of the results. None of the other variants was evaluated in meta-analysis.

In summary, through the use of a systematic review and inclusion of studies with validated RA efficacy endpoints, we identified six SNPs for which there is substantial evidence for an association with MTX response

in RA patients. For clinical application more evidence from prospective studies with multivariate testing is needed.

Acknowledgements We are particularly grateful for the assistance for search terms given by Jan Schoones of the Walaeus library (LUMC).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Lima A, Bernardes M, Azevedo R, Seabra V, Medeiros R. Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics. 2016. https://doi.org/10.2217/pgs-2016-0067.
2. Ulrich CM, Robien K, Sparks R. Pharmacogenetics and folate metabolism—a promising direction. Pharmacogenomics. 2002; 3:299–313.
3. Kawaida R, Yamada R, Kobayashi K, Tokuhiro S, Suzuki A, Kochi Y, et al. CUL1, a component of E3 ubiquitin ligase, alters lymphocyte signal transduction with possible effect on rheumatoid arthritis. Genes Immun. 2005;6:194–202.
4. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology. 2007;46:1520–4.
5. Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report R eview. Pharmacogenomics. 2013;14:305–14.
6. Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol. 2014;10:329–37.
7. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006;54:1366–77.
8. Brinker RR, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28. https://doi.org/10.3899/jrheum.091095.
9. Stamp L, Roberts R, Kennedy M, Barclay M, O'Donnell J, Chapman P. The use of low dose methotrexate in rheumatoid arthritis—are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed Pharmacother. 2006;60: 678–87.
10. Zhu H, Deng F-Y, Mo X-B, Qiu Y-H, Lei S-F. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Pharmacogenomics. 2014;15:551–66.
11. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005; 64:1180–5.
12. Ranganath VK, Khanna D, Paulus HE. ACR remission criteria and response criteria. Clin Exp Rheumatol. 2006;24:1909.
13. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35:745–57.
14. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med. 1997;127:380–7.
15. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
16. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, De Bakker PIW. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008;24:2938–9.
17. Senapati S, Singh S, Das M, Kumar A, Gupta R, Kumar U, et al. Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation. Pharmacogenet Genomics. 2014;24:211–9.
18. Ghodke-Puranik Y, Puranik AS, Shintre P, Joshi K, Patwardhan B, Lamba J, et al. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics. 2015;16:2019–34.
19. James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol. 2008;35: 562–71.
20. Grabar PB, Rojko S, Logar D, Dolzan V. Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway. Ann Rheum Dis. 2010;69:931–2.
21. Sharma Shruti, Das Mitashree, Kumar Ashok, Vishal Marwaha, Subramanian Shankar, Paramjeet Singh, et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. PubMed commons. Pharmacogenet Genomics. 2009;19:823–8.
22. Wessels JAM, Kooloos WM, De Jonge R, De Vries-Bouwstra JK, Allaart CF, Linssen A, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006;54:2830–9.
23. Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology. 2009;48:613–7.
24. Kurzawski M, Malinowski D, Szarmach N, Nowak A, Goryniak A, Pawlik A, et al. ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients. Pharmacogenomics. 2016;17:1971–8.
25. Swierkot J, Bogunia-Kubik K, Nowak B, Bialowas K, Korman L, Gebura K, et al. Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Jt Bone Spine. 2015; 82:94–9.
26. Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J Med Res. 2006;124:521–6.
27. Wessels JAM, De Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YPM, Allaart CF, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006;54:1087–95.
28. Taraborelli M, Andreoli L, Archetti S, Ferrari M, Cattaneo R, Tincani A. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor

with drug-related adverse events in an Italian population of rheumatic patients. Clin Exp Rheumatol. 2009;27:499–502.
29. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54:3095–103.
30. Dervieux T, Wessels JaMM, van der Straaten T, Penrod N, Moore JH, Guchelaar H-J, et al. Gene–gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics. 2009;19:935–44.
31. Lima A, Bernardes M, Azevedo R, Medeiros R, Seabra V. Pharmacogenomics of methotrexate membrane transport pathway: can clinical response to methotrexate in rheumatoid arthritis be predicted? Int J Mol Sci. 2015;16:13760–80.
32. Negi S, Kumar A, Thelma BK, Juyal RC. Association of Cullin1 haplotype variants with rheumatoid arthritis and response to methotrexate. Pharmacogenet Genomics. 2011;21:590–3.
33. Majorczyk E, Pawlik A, Gendosz D, Kuśnierczyk P. Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment. BMC Musculoskelet Disord. 2014;15:256.
34. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:3299–308.
35. Eektimmerman F, Swen JJ, Böhringer S, Huizinga TW, Kooloos WM, Allaart CF, et al. Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. Pharmacogenomics. 2017;18:945–53.
36. Muralidharan N, Mariaselvam CM, Jain VK, Gulati R, Negi VS. ATIC 347C>G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis. Pharmacogenomics. 2016;17:241–8.
37. Hayashi H, Tazoe Y, Tsuboi S, Horino M, Morishita M, Arai T, et al. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet. 2013;28:164–8.
38. Salazar J, Moya P, Altés A, Díaz-Torné C, Casademont J, Cerdà-Gabaroi D, et al. Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients? Pharmacogenomics. 2014;15:1079–90.
39. Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Aneja R, et al. Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics. 2008;18:1041–9.
40. Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar H-J. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics. 2010;11:163–75.
41. Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J. 2007;7:404–7.
42. Muralidharan N, Mariaselvam CM, Mithun CB, Negi VS. Reduced folate carrier-1 80G>A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis. Clin Rheumatol. 2016;35:879–85.
43. Moya P, Salazar J, Arranz MJ, Díaz-Torné C, del Río E, Casademont J, et al. Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. Pharmacogenomics. 2016;17:25–9.
44. Chatzikyriakidou A, Georgiou I, Voulgari PV, Papadopoulos CG, Tzavaras T, Drosos AA. Transcription regulatory polymorphism -43T>C in the 5′-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy. Rheumatol Int. 2007;27:1057–61.
45. van der Straaten R, Wessels JA, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Allaart CF, Bogaartz J, et al. Exploratory analysis of four polymorphisms in human *GGH* and *FPGS* genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics. 2007;8:141–50.
46. Wessels JAM, Van Der Kooij SM, Le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007;56:1765–75.
47. Milic V, Jekic B, Lukovic L, Bunjevacki V, Milasin J, Novakovic I, et al. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012;30:178–83.
48. Soukup T, Dosedel M, Pavek P, Nekvindova J, Barvik I, Bubancova I, et al. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients. Rheumatol Int. 2015;35:1149–61.
49. Kung TN, Dennis J, Ma Y, Xie G, Bykerk V, Pope J, et al. RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies. Arthritis Rheumatol. 2014;66:1111–20.
50. Li X, Hu M, Li W, Gu L, Chen M, Ding H, et al. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis. Int Immunopharmacol. 2016;38:8–15.